source
- BioNTech spends $205 million on FDA priority review voucher to accelerate oncology pipelineBioNTech has agreed to pay $205 million to acquire an FDA priority review voucher, a tool that can shorten the agency's standard review period from ten months to six months. The voucher was previo…
- Study warns German drug price hikes could raise US Medicaid spending by $300 millionA new Harvard Medical School study examined the effect of Germany's drug price increases on the United States under President Trump's most‑favored‑nation policy, which ties US federal drug pricing…